Phase 3 non-inferiority trial in 230 women in India with moderate-to-severe endometriosis pain: elagolix was non-inferior to dienogest for day-85 pain score change (difference 0.04; 95% CI -0.3 to 0.37). Adverse events 14.8% vs 19.1%.
RCTn = 230 women
Bhoir et al. Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate-to-Severe Endometriosis Pain: A Phase III, Multicentric, Double-Blind, Active-Controlled, Non-Inferiority Study